-
03.26.2025 Seikagaku Announces Revision of Forecast of Full-Year Consolidated Financial Results for the Fiscal Year Ending March 31, 2025
（3,853KB）
-
03.12.2025 Seikagaku Announces Receipt of a Complete Response Letter Concerning the Biologics License Application in the U.S. for SI-6603 (Generic Name: Condoliase)
（133KB）
-
02.21.2025 Seikagaku Announces Initiation of Phase III Clinical Studies of Gel-One, a Treatment of Osteoarthritis, in Japan
（3,943KB）
-
02.07.2025 Consolidated Financial Results for the Third Quarter of Fiscal year 2024
（218KB）
読む Consolidated Financial Results for the Third Quarter of Fiscal year 2024
Seikagaku News Releases are issued to provide stakeholders with the most up-to-date information related to our company.
-
02.07.2025 Seikagaku announced the financial results for the Third Quarter of the Fiscal Year ending March 31, 2025
-
01.24.2025 Seikagaku will announce the financial results for the Third Quarter of the Fiscal Year ending March 31, 2025 at 16:00 on February 7, 2025
-
12.02.2024 New Message from President & CEO
-
11.13.2024 Presentation Material for the Briefing on the Second Quarter FY2024 Financial Results
読む Presentation Material for the Briefing on the Second Quarter FY2024 Financial Results
